NCT04982289 2022-02-11Study of ALXN1830 Administered Subcutaneously in Adults With Generalized Myasthenia GravisAlexion Pharmaceuticals, Inc.Phase 2 Withdrawn
NCT03165435 2018-05-30A Study to Evaluate the Efficacy of CV-MG01 (Myasterix) in Myasthenia GravisCuraVacPhase 2/3 Withdrawn